glp 1 still hungry Why you are on your GLP‑1: or not hungry enough Still hungry on semaglutide? 9

The MIT team reported its initial findings in a preprint posted on bioRxiv , an online preprint server, on March 20

Vitamin C helps to stabilize glutathione in its active form, enhancing its antioxidant effects

Key Takeaways Gastrointestinal events are the most common adverse effects: Nausea, diarrhea, and vomiting were reported in 4067% of participants at higher doses in published Phase 2 trial data Adverse events are dose-dependent: Higher retatrutide doses consistently produced higher rates of GI events across all published trials Most adverse events were mild to moderate: The Phase 2 trial reported the majority of events as Grade 1-2 in severity Discontinuation rates ranged from 610%: Published data shows dropout rates due to adverse events were comparable to other GLP-1 class compounds Retatrutide is not FDA-approved: All safety data comes from investigational clinical trials it remains a research compound What Clinical Trials Tell Us About Retatrutide Adverse Events Retatrutide (LY3437943) is an investigational triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors simultaneously

Soria, J

Our clinical research showed the most noticeable results happen over 12 weeks

C.QinL.ReiterR